Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Colorcon
Fuji
Harvard Business School
Cantor Fitzgerald
Express Scripts

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 6,652,854

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,652,854
Title: Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
Abstract:The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF.alpha. inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF.alpha. inhibitors.
Inventor(s): Mohler; Kendall M. (Poulsbo, WA), Barone; Dauphine S. (Everett, WA), Kennedy; Mary K. (Seattle, WA)
Assignee: Immunex Corporation (Seattle, WA)
Application Number:09/921,667
Patent Claims:see list of patent claims

Details for Patent 6,652,854

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up Immunex Corporation (Seattle, WA) 2020-08-08 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up Immunex Corporation (Seattle, WA) 2020-08-08 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up Immunex Corporation (Seattle, WA) 2020-08-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Accenture
Fuji
Daiichi Sankyo
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.